Karyopharm Eyes Accelerated FDA Approval for Selinexor
NEWTON, Mass., July 30, 2026 Karyopharm Therapeutics Inc. plans to submit a supplemental New Drug Application (sNDA) to the...
Blood Cancer
Advertisement
CREATE, Monash Partner to Advance In Vivo CAR-T Platform
CAMBRIDGE, Mass., July 31, 2026 CREATE Medicines has announced a strategic research collaboration and exclusive worldwide licensing agreement with...
Curis Advances TakeAim CLL Trial with First Patients Dosed
LEXINGTON, Mass., July 30, 2026 Curis, Inc. has reached an important clinical milestone by successfully dosing the first five...
Genmab and AbbVie Clarify EPCORE DLBCL-1 Phase 3 Results
COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...
Organon, Samsung Bioepis Strengthen Australia Biosimilar Portfolio
SYDNEY, Australia & INCHEON, South Korea, July 16, 2026 Organon and Samsung Bioepis have expanded their longstanding partnership through...
Advertisements
ARUP Launches First Clinical Spectral Flow MRD Assay
SALT LAKE CITY, July 20, 2026 ARUP Laboratories has introduced ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry,...
PharmaEssentia Wins Canadian Approval for BESREMi in Rare Blood Cancer
BURLINGTON, Mass., July 6, 2026 PharmaEssentia Corporation announced that its wholly owned Canadian subsidiary, FORUS Therapeutics Inc., has received...
FDA Approves Tregzi to Prevent Chronic GVHD in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
FDA Approves Tregzi for Chronic GVHD Prevention in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, developed by Orca...
Samsung Bioepis Relaunches BYOOVIZ with Harrow in the U.S.
INCHEON, South Korea, July 1, 2026 Samsung Bioepis has officially announced the U.S. relaunch of BYOOVIZ® (ranibizumab-nuna), the first...
Advertisement
